CDT (CDT Equity) Change In Receivables: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDT CDT Equity Inc CDT
10 GF Score
Price $0.31
! 5 Warning Signs
View Full Analysis

What is CDT Equity Change In Receivables?

CDT Equity CDT -11.74% 10 Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

CDT Equity's change in receivables for the quarter that ended in Mar. 2026 was $0.00 Mil. It means CDT Equity's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

CDT Equity's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means CDT Equity's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

CDT Equity's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CDT Equity's liquidation value for the three months ended in Mar. 2026 was $-21.54 Mil.

CDT Equity  (NAS:CDT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CDT Equity's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, CDT Equity's accounts receivable are only considered to be worth 75% of book value:

CDT Equity's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.097-21.636+0.75 * 0+0.5 * 0
=-21.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Change In Receivables Related Terms

CDT Equity Change In Receivables Historical Data

* Premium members only.

The historical data trend for CDT Equity's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Change In Receivables Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00 0.00

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CDT
10GF Score
CDT Equity Inc CDT
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
CDT Equity (CDT) has a Change In Receivables of $0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for CDT Equity and its competitors.
Is CDT Equity's Change In Receivables too high?
CDT Equity's current Change In Receivables is $0.00 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Change In Receivables compare to CLDI and DCOY?
CDT Equity's Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for CDT Equity and its competitors. CDT Equity's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For CDT Equity (CDT), the current Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price